Citations

Showing 10 of 108083 citations.

Reply to E.R.S. Cliff et al
D’Souza, Anita , Kumar, Shaji , D'Souza, Anita

Mayo Clinic

Journal of Clinical Oncology | January 30, 2023 | Volume: 41 | Issue: 10 | Pages: 1951-1952

10.1200/jco.22.02691 | PMID 36716406 Get It

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.
Jones, Robin L. , Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Sprott, Kam , Achour, Haroun, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Jones, Robin L , Bauer, Sebastian , George, Suzanne , Gelderblom, Hans , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Trent, Jonathan C. , Reichmann, William M. , Blay, Jean‐Yves , Heinrich, Michael C.

Mayo Clinic

Journal of Clinical Oncology | January 30, 2023 | Volume: 41 | Issue: 36_suppl | Pages: 397784-397784

10.1200/jco.2023.41.36_suppl.397784 Get It

397784 Background: Ripretinib, a switch-control tyrosine kinase inhibitor (TKI), is indicated for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with ≥3 TKIs, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. Circulating tumor DNA (ctDNA) analysis may provide insight into the efficacy of these agents in second-line advanced GIST. Here, we present exploratory baseline ctDNA results from INTRIGUE. Methods: INTRIGUE is an open-label, phase 3 study that enrolled adult pts with advanced GIST who progressed on or had intolerance to imatinib (NCT03673501). Randomization was 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off). Baseline peripheral whole blood was analyzed by Guardant360, a 74-gene ctDNA next-generation sequencing (NGS)-based assay. Only KIT mutations are reported here. Results: Of 453 pts in the overall intent-to-treat (ITT) population, 362 (80%) samples were analyzed. ctDNA was detected in 280/362 (77%), with KIT mutations detected in 213/280 (76%). Common resistance mutations were in the KIT activation loop (AL; exons 17/18; 89/213, 42%) and ATP-binding pocket (ATP-BP; exons 13/14; 81/213, 38%). Efficacy in pts with detectable ctDNA in the KIT exon 11 and overall ITT populations was consistent with the primary analysis based on tumor data used for randomization. Pts with KIT exon 11 + 17/18 (−9/13/14) mutations had superior progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) with ripretinib vs sunitinib, whereas pts with exon 11 + 13/14 (−9/17/18) mutations had better PFS, ORR, and OS with sunitinib vs ripretinib (Table). Subgroup safety profiles were consistent with the primary analysis. Conclusions: While KIT ATP-BP mutations predicted clinical benefit from sunitinib vs ripretinib, pts harboring resistance mutations in the KIT AL derived meaningful clinical benefit from ripretinib but not sunitinib. This study demonstrates the value of ctDNA NGS-based sequencing of the complex landscape of KIT mutations to predict the clinical benefit of ripretinib or sunitinib as second-line therapy in pts with advanced GIST. Clinical trial information: NCT03673501 . [Table: see text]
Standardization of the Definition and Surgical Management of Splenic Flexure Carcinoma by an International Expert Consensus Using the Delphi Technique: Room for Improvement?
Benlice, Cigdem , Parvaiz, Amjad , Hohenberger, Werner , Mišković, Danilo , Stocchi, Luca , Steele, Scott, Kim, Seon Hahn , Holm, Torbjörn, Spinelli, Antonino , Gögenür, Ismail , Panís, Yves , Hasegawa, Hirotoshi , Uriburu, Juan C Patrón , Croner, Roland S. , Keßler, Hermann, Group, On behalf of the Splenic Flexure Cancer Delphi Consensus Study, Spinelli, Antonino , Benlice, Çiğdem , Baca, Bilgi , Карачун, А. М. , Ito, Masaki A. , Kuzu, Mehmet Ayhan , Group, On behalf of the Splenic Flexure Cancer Delphi Consensus Study

Mayo Clinic

Diseases of the Colon & Rectum | January 30, 2023 | Volume: 66 | Issue: 6 | Pages: 805-815

10.1097/dcr.0000000000002692 | PMID 36716403 Get It

BACKGROUND: Surgical management of splenic flexure carcinoma remains controversial. OBJECTIVE: This study aimed to establish an expert international consensus on splenic flexure carcinoma management. DESIGN: A 3-round online-based Delphi study was conducted between September 2020 and April 2021. SETTING: The first round included 18 experts from 12 different countries. For the second and third rounds, each expert in the first round was asked to invite 2 more colorectal surgeons (n = 47). Out of 47 invited experts, 89% (n = 42) participated in the second and third rounds of the consensus. INTERVENTIONS: A total of 35 questions were created and sent via the online questionnaire tool. MAIN OUTCOME MEASURES: Levels of recommendation based on voting concordance were graded as follows: more than 75% agreement was defined as strong, between 50% and 75% as moderate, and below 50% as weak. RESULTS: There was moderate consensus on the definition of splenic flexure (55%) as 10 cm from either side where the distal transverse colon turns into the proximal descending colon. Also, experts recommended an abdominopelvic CT scan plus intraoperative exploration (moderate consensus, 72%) for tumor localization and cancer registry. Segmental colectomy was the preferred technique for the management of splenic flexure carcinoma in the elective setting (72%). Moderate consensus was achieved on the technique of complete mesocolic excision and central vascular ligation principles for splenic flexure carcinoma (74%). Only strong consensus was achieved on the surgical approach for minimally invasive surgery (88%). LIMITATIONS: Subjective decisions are based on individual expert clinical experience and not evidence based. CONCLUSIONS: This is the first internationally conducted Delphi consensus study regarding splenic flexure carcinoma. The definition of splenic flexure remains ambiguous. To more effectively compare oncologic outcomes among different cancer registries, guidelines need to be developed to standardize each domain and avoid arbitrary definitions. See Video Abstract at http://links.lww.com/DCR/C143. ESTANDARIZACIÓN DE LA DEFINICIÓN Y MANEJO QUIRÚRGICO DEL CARCINOMA DE ÁNGULO ESPLÉNICO ESTABLECIDO POR UN CONSENSO INTERNACIONAL DE EXPERTOS UTILIZANDO LA TÉCNICA DELPHI: ¿ESPACIO PARA MEJORAR? ANTECEDENTES: El tratamiento quirúrgico del cáncer de ángulo esplénico sigue siendo controvertido. OBJETIVO: Establecer un consenso internacional de expertos sobre el manejo del cáncer del ángulo esplénico. DISEÑO: Se condujo un estudio Delphi en línea de 3 rondas entre septiembre de 2020 y febrero de 2021. ESCENARIO: La primera ronda incluyó a 18 expertos de 12 países distintos. Para la segunda y tercera rondas, a cada experto de la primera ronda se le pidió que invitara a 2 cirujanos colorrectales más de su región (n = 47). De los 47 expertos invitados, el 89% (n = 42) participó en la segunda y tercera ronda del consenso. INTERVENCIONES: Se crearon y enviaron un total de 35 preguntas a través de la herramienta de cuestionario en línea. PRINCIPALES MEDIDAS DE RESULTADO: Los niveles de recomendación basados en la concordancia de votos fueron jerarquizados de la siguiente manera: más del 75% de acuerdo se definió como fuerte, entre 50 y 75% como moderado y por debajo del 50% como débil. RESULTADOS: Hubo un consenso moderado sobre la definición de ángulo esplénico (55%) como 10 cm desde cualquier lado donde el colon transverso distal se convierte en el colon descendente proximal. Así también, los expertos recomendaron la tomografía computarizada abdominopélvica más la exploración intraoperatoria (consenso moderado, 72%) para la localización del tumor y el registro del ángulo esplénico. La colectomía segmentaria fue la técnica preferida para el tratamiento del cáncer de ángulo esplénico en el caso de ser electivo (72%). Se logró un consenso moderado sobre la técnica de escisión completa del mesocolon y los principios de ligadura vascular a nivel central para el cáncer de ángulo esplénico (74%). Solo se logró un fuerte consenso sobre el abordaje quirúrgico para la cirugía mínimamente invasiva (88%). LIMITACIONES: Decisiones subjetivas basadas en la experiencia clínica de expertos individuales y no basadas en evidencia. CONCLUSIONES: Este es el primer estudio internacional de consenso Delphi realizado sobre el cáncer de ángulo esplénico. Si bien encontramos un consenso moderado sobre las modalidades de diagnóstico preoperatorio y el manejo quirúrgico, la definición de ángulo esplénico sigue siendo ambigua. Para comparar de manera más efectiva los resultados oncológicos entre diferentes registros de cáncer, se deben desarrollar pautas para estandarizar cada dominio y evitar definiciones arbitrarias. Consulte Video Resumen en http://links.lww.com/DCR/C143. (Traducción—Dr. Osvaldo Gauto )
Dual infection with Alternaria and Nocardia in a renal transplant patient
Gupta, Simran , Cunningham, Cody A. , Grant, Leah M., Abdou, Merna , Seville, Maria Teresa , Abdou, Merna M, Graf, Erin H.

Mayo Clinic

Transplant Infectious Disease | January 30, 2023 | Volume: 25 | Issue: 3 | Pages: No page available

10.1111/tid.14026 | PMID 36715649 Get It

Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group
Rakela, Jorge , Karvellas, Constantine , Koch, David , Vegunta, Suneela , Lee, William M. , Rakela, Jorge , Karvellas, Constantine , Koch, David

Mayo Clinic

Clinical and Translational Gastroenterology | January 30, 2023 | Volume: 14 | Issue: 4 | Pages: e00565

10.14309/ctg.0000000000000565 | PMID 36716224 Get It

There has been a growing interest in identifying prognostic biomarkers that alone or with available prognostic models (King’s College Criteria, KCC; MELD and ALFSG Prognostic Index) would improve prognosis in acute liver failure (ALF) patients being assessed for liver transplantation. The Acute Liver Failure Study Group (ALFSG) has evaluated 15 potential prognostic biomarkers: serum AFP; apoptosis-associated proteins; serum actin-free Gc-globulin; serum glycodeoxycholic acid; sRAGE/RAGE ligands; plasma osteopontin; circulating MBL, M-, L-, H-ficolin and CL-1; plasma galectin-9; serum FABP1; serum Lct2; miRNAs; factor V; thrombocytopenia, and sCD163. The ALFSG also has reported on 4 susceptibility biomarkers: keratins 8 and 18 (K8/K18) gene variants; polymorphisms of genes encoding putative APAP-metabolizing enzymes ( UGT1A1 , UGT 1A0 , UGT 2B15 , SULT1A1 , CYP2E1 , and CYP3A5 ) as well as CD44 and BHMT1 ; single nucleotide polymorphisms (SNPs) of genes associated with human behavior, rs2282018 in the arginine vasopressin ( AVP ) gene and rs11174811 in the AVP receptor 1A gene. Finally, rs2277680 of the CSCL16 gene in HBV-ALF patients. In conclusion, we have reviewed the prognostic and susceptibility biomarkers studied by the ALFSG. We suggest that a better approach to predicting the clinical outcome of an ALF patient will require a combination of biomarkers of pathogenic processes such as cell death, hepatic regeneration, and degree of inflammation that could be incorporated into prognostic models such as KCC, MELD or ALFSG PI.
RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome
Tibes, Raoul

Mayo Clinic

EMJ Hematology | January 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: 53-57

10.33590/emjhematol/10314849 Get It

Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced myeloproliferative neoplasm (MPNs) has been slow. This is partially due to the heterogeneity of the diseases and the lack of molecular understanding, which delays effective drug development. There will be potentially three rather effective avenues to arrive at novel molecular vulnerabilities that can be therapeutically exploited. First, is identifying disease-specific mutations or other genomic aberrations (i.e. translocations, aberrant methylation) that will result in targeting affected and closely associated genes. Second, is tracing disease evolution over time, clonal evolution by various approaches, many of which will include current genomic tools and assays. Third, a more unbiased, broad discovery approach either with small molecule screens or, in our opinion, by identification of specific molecular vulnerabilities by RNA interference (RNAi). RNAi is a mechanistically rather agnostic high-throughput approach to find essential targets, alone or in combination with commonly used anti-cancer agents. In this paper we will briefly summarise some ideas and early results of RNAi screens, with a focus on hypomethylating agents and how RNAi can identify rational combination therapies with 5-azacytidine that can be rapidly translated into the clinical setting.
Above-The-Hairline Suboccipital Transverse Approach for the Treatment of Chiari I Malformation
Naylor, Ryan M. , Rotter, Juliana , Proctor, Mark R. , Bite, Uldis, Ahn, Edward S.

Mayo Clinic

Operative Neurosurgery | January 30, 2023 | Volume: 24 | Issue: 5 | Pages: 542-547

10.1227/ons.0000000000000619 | PMID 36716002 Get It

BACKGROUND: Chiari I malformation is a common pediatric neurosurgical disorder with an established treatment paradigm. Posterior fossa decompression and duraplasty (PFDD) is associated with symptom improvement but it carries postoperative risk, particularly cerebrospinal fluid (CSF) leak and wound complications. In addition, the cosmetic outcomes of PFDD have been overlooked in the literature. OBJECTIVE: To describe a novel approach for PFDD in which the transverse surgical incision is completely hidden above the hairline and to report early outcomes in a prospective patient cohort. METHODS: Clinical and cosmetic outcomes were recorded for 15 consecutive pediatric patients who underwent PFDD for Chiari I malformation via the above-the-hairline transverse suboccipital approach. RESULTS: The median clinical follow-up time was 6 months (range 1-12 months), and the majority of patients experienced significant improvement of their preoperative symptoms. Three patients (20%) experienced complications associated with surgery, which included injury to the greater occipital nerve, CSF hypotension and subfascial pseudomeningocele, and superficial wound dehiscence that resolved spontaneously with oral antibiotics. Zero patients (0%) returned to the operating room for persistent CSF leak, deep wound infection, or revision decompression. An excellent cosmetic outcome was achieved in 12 patients (80%). No patient had a poor cosmetic outcome. CONCLUSION: The above-the-hairline transverse suboccipital approach for PFDD in patients with Chiari I malformation offers favorable cosmetic outcomes and fascial closure while permitting adequate decompression.
Antineutrophil cytoplasmic antibody–associated vasculitis and VEXAS syndrome: comment on the article by Muratore et al
Koster, Matthew J. , Ghaffar, Umar , Kermani, Tanaz A. , Patnaik, Mrinal M. , Mangaonkar, Abhishek A. , Reichard, Kaaren K. , Olteanu, Horatiu , Koster, Matthew J , Go, Ronald S. , Warrington, Kenneth J.

Mayo Clinic

Arthritis & Rheumatology | January 30, 2023 | Volume: 75 | Issue: 8 | Pages: 1490-1492

10.1002/art.42466 | PMID 36716119 Get It

Physiology-Based Approach to PEEP Titration in COVID-19 ARDS
Cortes-Puentes, Gustavo A. , Gattinoni, Luciano , Marini, John J.

Mayo Clinic

Respiratory Care | January 30, 2023 | Volume: 68 | Issue: 2 | Pages: 290-292

10.4187/respcare.10811 | PMID 39889138 Get It

Impact of an Online Program of Bubble Continuous Positive Airway Pressure Education in a Resource-Constrained Setting
Annankra, Wentiirim B. , Mavis, Stephanie C. , Shany, Eilon , Jacob, Binil Mathew , Bakari, Ashura , Yeboah, Rita , Karplus, Miki, Carey, William A., Golan, Agneta, Jacob, Binil M , Mavis, Stephanie

Mayo Clinic

ATS Scholar | January 30, 2023 | Volume: 4 | Issue: 1 | Pages: 87-95

10.34197/ats-scholar.2022-0069in | PMID 37089689 Get It

Abstract Background Respiratory distress is a leading cause of preterm infant mortality in sub-Saharan Africa. Bubble continuous positive airway pressure (CPAP) is emerging as a potentially safe, cost-effective way of delivering noninvasive respiratory support in low-income and middle-income countries. However, without healthcare providers who are knowledgeable and skilled in the use of this technology, suboptimal neonatal care and related health disparities are likely to persist. Objective We hypothesized that an Internet-based, blended curriculum on bubble CPAP for bedside providers in low-resource mother-baby units (MBUs) could be developed and implemented and lead to improvements in clinical knowledge, reasoning, and learner confidence in bubble CPAP. Methods Clinical educators from Israel, Ghana, and the United States used the analysis, design, development, implementation, and evaluation (ADDIE) design framework to create an online curriculum for two MBUs in Kumasi, in the Ashanti Region of Ghana. Participants completed pre and post curriculum knowledge tests and completed surveys on their perspectives. Results Fifty-four interdisciplinary health professionals from the MBUs participated in the curriculum. Median knowledge test scores improved from 64% (interquartile range [IQR] = 50–72%) to 81% (IQR = 71–89%) after participation in the curriculum (P < 0.001). Learners reported high levels of confidence with bubble CPAP after participating in the curriculum and evaluated the curricular components highly. Conclusion An online curriculum was successfully implemented and led to changes in healthcare worker knowledge in bubble CPAP. This may be an effective way to deliver education to healthcare professionals in resource-constrained countries and warrants further study.